Autoimmune Liver Disease — Viva Defence

Long Case Viva Defence

The scenario

A 54-year-old woman presents with a 12-month history of progressive fatigue and pruritus, and a 3-month history of painless jaundice. She has hypothyroidism but no other past history. Blood tests show ALP 520 U/L, gamma-GT 390 U/L, bilirubin 75 micromol/L, ALT 180 U/L, albumin 33 g/L, IgM 4.8 g/L (raised), IgG 28 g/L (raised, upper limit 16). AMA positive at 1:640, ANA positive at 1:5120, SMA positive at 1:160, anti-LKM1 negative. IgG4 normal. Liver biopsy shows a florid duct lesion AND interface hepatitis with a plasma-cell infiltrate. Ultrasound shows normal biliary ducts. FibroScan 14 kPa (consistent with cirrhosis). ^[1]

Opening statement (SASPOP)

"This is Mrs K, a 54-year-old woman presenting with a 12-month history of fatigue and pruritus and a 3-month history of jaundice, found to have an AIH-PBC overlap syndrome — she meets the Paris criteria for both diseases, with a cholestatic LFT pattern, a positive AMA, a raised IgM and a florid duct lesion for PBC, plus a hepatocellular component, a raised IgG, positive ANA and SMA, and interface hepatitis with a plasma-cell infiltrate for AIH. Her FibroScan of 14 kPa indicates established cirrhosis. Her main problems are the overlap syndrome, which needs a combined UDCA and immunosuppressive strategy; the cirrhosis with its surveillance requirements; the pruritus; the osteoporosis risk from both the cholestasis and the corticosteroids I will use; and the psychosocial impact of a complex chronic diagnosis. My priorities are to start ursodeoxycholic acid for the PBC component, check the TPMT activity and then start prednisolone plus azathioprine for the AIH component, stage and surveil the cirrhosis, manage the pruritus and the bone health, and involve a multidisciplinary team including hepatology, dietetics and the GP." ^[1]

Problem list (numbered, prioritised)

1. AIH-PBC overlap syndrome — the central problem; needs combined UDCA and immunosuppression.
2. Cirrhosis (FibroScan 14 kPa) — requires variceal and HCC surveillance.
3. Pruritus — a major quality-of-life issue.
4. Osteoporosis risk — from cholestasis and corticosteroids.
5. Fat-soluble vitamin deficiency — likely given the cholestasis and jaundice.
6. Hypothyroidism — a common associated autoimmune condition; ensure it is well replaced.
7. Psychosocial impact and communication — complex chronic diagnosis, lifelong therapy. ^[1]

Integrated management plan

Pillar 1 — Ursodeoxycholic acid for the PBC component: "I would start UDCA at 13 to 15 mg/kg/day in divided doses, first-line for all stages of PBC. The 1994 Lindor NEJM trial showed it slows histological progression and reduces the need for transplant ^[2]. This is lifelong therapy."

Pillar 2 — Immunosuppression for the AIH component: "I would add prednisolone 0.5 to 1 mg/kg/day plus azathioprine 1 to 2 mg/kg/day. Critically, I would check the thiopurine methyltransferase (TPMT) activity BEFORE starting azathioprine, because TPMT deficiency causes fatal myelosuppression ^[5]. I would monitor the full blood count weekly for the first month, then monthly. Because she has established cirrhosis, I would use prednisolone rather than budesonide — budesonide is ineffective in cirrhosis because of portosystemic shunting."

Pillar 3 — Cirrhosis surveillance: "FibroScan confirms cirrhosis. I would arrange an upper GI endoscopy for variceal surveillance, six-monthly ultrasound plus alpha-fetoprotein for hepatocellular carcinoma, and a DEXA for bone density. I would check the fat-soluble vitamin levels and replace as needed." ^[1]

Pillar 4 — Symptom control: "For the pruritus, I would start cholestyramine, given separately from UDCA by at least 2 to 4 hours. If inadequate, add rifampicin 150 to 300 mg twice daily with liver function monitoring, then naltrexone or sertraline. For the fatigue, there is no specific therapy — I would exclude anaemia, hypothyroidism and vitamin D deficiency, and address sleep, mood and deconditioning." ^[1]

Pillar 5 — Bone and nutritional health: "Calcium and vitamin D supplementation, and a bisphosphonate if the DEXA shows osteoporosis. Steroid-sparing measures: monitor blood glucose and blood pressure, and consider an early switch to azathioprine monotherapy as the prednisolone is tapered." ^[1]

Pillar 6 — Second-line and transplant: "If her biochemistry does not normalise, I would consider adding obeticholic acid — but ONLY if her cirrhosis is compensated (Child-Pugh A). OCA is contraindicated in decompensated cirrhosis because it can precipitate liver failure ^[3]. If she develops decompensation (ascites, encephalopathy, variceal bleed, rising bilirubin), I would refer for liver transplant assessment."

Probing questions the examiner would ask

Q: How do you apply the Paris criteria for AIH-PBC overlap in this patient? ^[1]

A: "The Paris criteria require two of three AIH features AND two of three PBC features. For AIH: moderate/severe interface hepatitis; ALT above five times the upper limit; IgG above twice the upper limit OR positive SMA. She meets two of the three — interface hepatitis on biopsy and positive ANA/SMA with a raised IgG (her ALT of 180 sits below the five-times threshold) — which satisfies the AIH component. For PBC: ALP above twice the upper limit; AMA positive; florid duct lesion. She meets all three — ALP 520, AMA 1:640, florid duct lesion. So she has definite overlap. The IAIHG position statement (Boberg 2011) cautions that overlap is partly a research concept and patients should be treated for their predominant feature, but here both diseases are clearly active and a combined strategy is justified ^[7]."

Q: Why did you check the IgG4, and what would a raised IgG4 have meant? ^[1]

A: "I checked the IgG4 to exclude IgG4-related sclerosing cholangitis, the steroid-responsive mimic of PSC. A raised IgG4 in a cholestatic patient, especially an older man with a strictured cholangiogram and autoimmune pancreatitis, would indicate IgG4-sclerosing cholangitis, whose treatment is systemic corticosteroids — the opposite of PSC, which is not steroid-responsive. In this patient the normal IgG4 and the classic PBC features (AMA, raised IgM, florid duct lesion) make IgG4-disease unlikely, but the check is part of the standard cholestatic workup." ^[1]

Q: Why are you using prednisolone rather than budesonide for the AIH component? ^[1]

A: "Budesonide is a first-pass corticosteroid that achieves high hepatic concentrations with minimal systemic exposure, making it an attractive steroid-sparing option in non-cirrhotic AIH. However, in cirrhosis the portosystemic shunting bypasses the first-pass metabolism, so budesonide behaves like systemic prednisolone without the steroid-sparing benefit — and it is contraindicated in cirrhosis. This patient has established cirrhosis on FibroScan, so prednisolone is the correct choice, with diligent attention to bone density, blood glucose and blood pressure." ^[1]

Q: What is the role of obeticholic acid in this patient, and what are the cautions? ^[1]

A: "OCA is a farnesoid X receptor agonist, shown in the 2016 POISE trial to improve the composite of ALP and bilirubin in patients with an inadequate response to UDCA ^[3]. In this patient, if her PBC biochemistry does not respond to UDCA plus immunosuppression, I would consider adding OCA — but only if her cirrhosis is compensated (Child-Pugh A). OCA is contraindicated in decompensated (Child-Pugh B and C) cirrhosis because it can precipitate liver failure and death. It also commonly worsens pruritus, which is the commonest reason to reduce the dose or stop the drug. The dose is 5 mg daily for six months, then 10 mg daily if the target is not met, with dose reduction to once weekly in stage 4 compensated cirrhosis."

Q: What surveillance does she need for her cirrhosis? ^[1]

A: "Upper GI endoscopy for variceal surveillance at diagnosis and every one to three years depending on findings; six-monthly ultrasound plus alpha-fetoprotein for hepatocellular carcinoma; a baseline and biennial DEXA for osteoporosis; and annual fat-soluble vitamin levels (A, D, E, K) given her cholestasis. If she develops any feature of decompensation — ascites, encephalopathy, variceal bleed, a rising bilirubin — I would refer her for liver transplant assessment." ^[1]

Q: How would her management change if she wanted to become pregnant? ^[1]

A: "I would plan pregnancy for when the disease is in biochemical remission. UDCA is safe in pregnancy and should be continued. Prednisolone and azathioprine are considered compatible with pregnancy and should be continued. Mycophenolate mofetil (if she were on it) is teratogenic and must be stopped at least six weeks before conception. I would counsel that there is a risk of a disease flare in the postpartum period (within three to six months), so I would monitor her closely then. The cirrhosis complicates pregnancy and I would involve a maternal-fetal medicine specialist and a hepatologist in a joint clinic." ^[1]

Communication and shared decision-making

"I would explain the diagnosis in plain language — that her immune system is attacking both the bile ducts and the liver cells, which is why she has features of two diseases, and the treatment needs to address both. I would explain that the UDCA is for the bile duct disease (lifelong), and the prednisolone and azathioprine are for the immune attack on the liver cells (at least 24 months before we consider withdrawal). I would be honest about the chronicity, the surveillance burden, the corticosteroid side effects, and the transplant possibility if the disease progresses. I would involve the GP, the dietitian, the physiotherapist, and a hepatology nurse specialist. I would document the shared decisions and review them as the biochemistry responds." ^[1]